Neuland Laboratories, a global contract development and manufacturing organization (CDMO) specializing in complex APIs, has announced that Saharsh Davuluri will assume the role of Chief Executive Officer (CEO) and Managing Director, effective immediately, as the company moves into its next stage of growth.

Davuluri has been with the company for more than 18 years and will position the CDMO as a premier global API process development and commercial manufacturing specialist. According to the company, his recent successes have been built on a growing reputation for scale-up of complex APIs and peptides, and the business has tripled its contract services revenues during the last 3-years.

At DCAT Week, Contract Pharma met with Davuluri for an exclusive interview.

“It’s an incredibly exciting time for the wider CDMO sector, and for Neuland in particular, as global innovators increasingly come to us with their most complex chemistries and scale-up challenges. But we have not rested on these successes, and I will now be looking to further accelerate this growth transformation over the next five years. We have already committed to a four-phase expansion of commercial peptide capacity and are also doubling our process development capabilities,” said Davuluri. “The secret sauce behind our recent commercial success, however, has been our incredibly strong reputation for specialist process chemistries, accelerated development timelines and, of course, consistent commercial supply. Building scale is important, but our team’s reputation as problem solvers and process innovators, coupled with consistent CMC delivery, is the real driver behind our rapidly growing number of biotech and big pharma partners.”

The company’s CDMO investment approach is built around the innovation pipelines of its customers. So, Neuland continues to structure its teams and capabilities to meet the evolving development needs of its partners.